(2009). a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
Dapagliﬂozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care
(2009). Dapagliﬂozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther
Discovery of dapagliﬂozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Effect of dapagliﬂozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.
(2009). Fiedorek FT. A study of dapagliﬂozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care
(2011). Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol 2010;299:C1277–C1284 FIG. 1. Renal glucose handling. Flux rates (ﬁltration, reabsorption, and excretion) were calculated using a glomerular ﬁltration rate of 120 mL
Glucose transport by human renal
(2005). Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes
Inhibitor binding in the human renal low- and high-afﬁnity Na+/glucose cotransporters.
Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects.
Molecular analysis of the SGLT2 gene in patients with renal glucosuria.
(1994). Molecular physiology of sodium-glucose cotransporters.
Neuronal regulation of homeostasis by nutrient sensing.